Patents by Inventor Jeff Sterling

Jeff Sterling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 6528685
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: March 4, 2003
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Mitchell Shirvan, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
  • COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES
    Publication number: 20020068839
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Application
    Filed: October 19, 1999
    Publication date: June 6, 2002
    Inventors: SASSON COHEN, YAACOV HERZIG, RUTH LEVY, MITCHELL SHIRVAN, JEFF STERLING, ALEX VEINBERG, MOUSSA B. H. YOUDIM, JOHN P. M. FINBERG
  • Pharmaceutical compositions comprising S-(?)-N-propargyl-1-aminoindan
    Patent number: 6277886
    Abstract: Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(−)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: August 21, 2001
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Ruth Levy, Moussa B. H. Youdim, John P. M. Finberg, Sasson Cohen, Jeff Sterling
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 6271263
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: August 7, 2001
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Benjamin Sklarz, Ramy Lidor, Eliezer Bahar, Yaacov Herzig, Jeff Sterling, Alex Veinberg
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 5994408
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: November 30, 1999
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research & Development Foundation, Ltd.
    Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Tzipora Speiser, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 5914349
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 22, 1999
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Mitchell Shirvan, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 5880159
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: March 9, 1999
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Yaacov Herzig, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg, Naim Sayag
  • Derivatives of tetramethylcyclopropane
    Patent number: 5880157
    Abstract: The present invention relates to derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid (TMCA) of general formula (I), ##STR1## wherein R is lower alkyl group (C.sub.1 -C.sub.6), an aryl group, an aralkyl group or an amide of general formula (II), ##STR2## where R.sub.1 and R.sub.2 are the same or different and may be hydrogen, a alkyl group (C.sub.1 -C.sub.6), an aryl group or an aralkyl group, and n=0-3, to their racemic mixtures and the D and L enantiomers. The invention also relates to processes for the preparation of said compounds and for pharmaceutical preparations comprising the same. The new compounds show improved activity against epilepsy.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: March 9, 1999
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Jeff Sterling, Yaacov Herzig, Meir Bialer, Abdullah Haj-Yehia, Boris Yagen
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 5877221
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: March 2, 1999
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
  • Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
    Patent number: 5877218
    Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 2, 1999
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Yaacov Herzig, Jeff Sterling, Alex Veinberg, Benjamin Sklarz, Ramy Lidor, Eliezer Bahar
  • Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
    Patent number: 5585358
    Abstract: A compound having the structure: ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are independently the same or different and are hydrogen, a C.sub.1 -C.sub.6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3. Also provided are a compound containing a 2-valproenoic moiety, pharmaceutical compositions comprising these compounds, and methods of using them for the effective treatment of epilepsy and other neurological disorders.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: December 17, 1996
    Assignees: Yissum Research Development Corporation of the Hebrew University of Jerusalem, Teva Pharmaceutical Industries Ltd.
    Inventors: Meir Bialer, Salim Hadad, Jacob Herzig, Jeff Sterling, David Lerner, Mitchell Shirvan
  • Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
    Patent number: 5486541
    Abstract: N-propargyl-1-amonoindan monofluorinated in the phenyl ring and their use as selective inhibitors of monoamine oxidase (MAO).There are provided several processes for the preparation of these novel compounds. There are also provided as novel compounds 1-aminoindans monofluorinated in the phenyl ring, which serve as intermediates in the preparation of the corresponding novel N-propargyl derivatives.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: January 23, 1996
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Jeff Sterling, Ruth Levy, Alex Veinberg, Willy Goldenberg, John Finberg, Musa Youdim, Arieh Gutman
  • Water-soluble analogs of carbamazepine
    Patent number: 5466683
    Abstract: The present invention relates to novel water-soluble analogs of carbamazepine and compositions containing them. The novel compositions are particularly suited for intravenous administration. The analogs of carbamazepine are useful in the treatment of epilepsy and related disorders.
    Type: Grant
    Filed: August 25, 1994
    Date of Patent: November 14, 1995
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Jeff Sterling, Yaacov Herzig